Am­gen en­ters weight loss mar­ket with drug that shows 14.5% weight re­duc­tion

Ear­ly da­ta of Am­gen’s weight loss drug Mar­i­Tide showed com­pa­ra­ble weight loss to pop­u­lar drugs on the mar­ket and in de­vel­op­ment, with pa­tients on the high­est dose los­ing an av­er­age of 14.5% of their weight over 85 days.

Am­gen test­ed its mol­e­cule in 133 obese but non­di­a­bet­ic pa­tients in a Phase I study, pub­lished Mon­day in Na­ture Me­tab­o­lism. The bis­pe­cif­ic mol­e­cule, which is made by con­ju­gat­ing a mon­o­clon­al an­ti-hu­man GIPR an­tag­o­nist an­ti­body to two GLP-1 ana­log ag­o­nist pep­tides, al­so showed a safe­ty pro­file sim­i­lar to GLP-1s. The most com­mon ad­verse events were most­ly mild cas­es of nau­sea and vom­it­ing and re­solved af­ter two days.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER